In recent years, immunotherapy and molecularly targeted therapy research have advanced rapidly, with the combined anti‐PD‐L1 (programmed cell death‐Ligand 1) antibody atezolizumab and VEGF(vascular endothelial growth factor)‐neutralizing antibody bevacizumab becoming the standard first‐line therapy for HCC,3 but the effect of immunotherapy on nonalcoholic steatohepatitis (NASH) and HCC is completely unclear, so the application of immunotherapy in HCC has not achieved very satisfactory results.4 This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatohepatitis.